Why 90% of Cancer Drugs Fail: Data Gaps, Weak Models and Siloed Insights in Oncology
burny_tech · x · 2026-10-10
- An industry analysis examines why roughly 90% of cancer drugs fail, attributing it to systemic data problems in oncology R&D.
- Three root causes: data gaps (missing key experimental and real-world evidence), weak models (poor predictive power of current disease and drug-response models), and siloed insights (knowledge fragmented across institutions and papers).
- The piece argues better data infrastructure and modeling are key to raising success rates.
More from Research
- Embedding arithmetic demo: cartoon − animation − comic = diagram — mayfer · 2026-10-23
- Omnii Genome: Single Generalist Model Outperforms AlphaGenome Across All Benchmarks — JosephJacks_ · 2026-10-23
- Domingos Cites New Result Claiming RL Is 'Basically Useless' vs Supervised Learning — pmddomingos · 2026-10-23
- Word Arithmetic on Embeddings: "Bathroom Minus Toilet Equals Kitchen" Beats SAE Probing — mayfer · 2026-10-23
- Wolfram Opens Rule 30 Prizes to AIs: $30,000 for Three Open Problems — cephaloform · 2026-10-23
- Stanford and Databricks use AI agents to reproduce medical findings and test analytical robustness — ChengleiSi · 2026-10-23